Myriad Genetics (MYGN) Competitors $6.22 +0.29 (+4.89%) Closing price 04:00 PM EasternExtended Trading$6.15 -0.07 (-1.13%) As of 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MYGN vs. BCRX, CLDX, NVAX, INVA, MNKD, DVAX, OPK, GERN, RIGL, and ZBIOShould you be buying Myriad Genetics stock or one of its competitors? The main competitors of Myriad Genetics include BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Novavax (NVAX), Innoviva (INVA), MannKind (MNKD), Dynavax Technologies (DVAX), OPKO Health (OPK), Geron (GERN), Rigel Pharmaceuticals (RIGL), and Zenas BioPharma (ZBIO). These companies are all part of the "biotechnology" industry. Myriad Genetics vs. Its Competitors BioCryst Pharmaceuticals Celldex Therapeutics Novavax Innoviva MannKind Dynavax Technologies OPKO Health Geron Rigel Pharmaceuticals Zenas BioPharma BioCryst Pharmaceuticals (NASDAQ:BCRX) and Myriad Genetics (NASDAQ:MYGN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability. Which has more volatility and risk, BCRX or MYGN? BioCryst Pharmaceuticals has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.89, suggesting that its stock price is 89% more volatile than the S&P 500. Do insiders & institutionals have more ownership in BCRX or MYGN? 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are held by institutional investors. 5.1% of BioCryst Pharmaceuticals shares are held by insiders. Comparatively, 2.4% of Myriad Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has higher valuation & earnings, BCRX or MYGN? BioCryst Pharmaceuticals has higher earnings, but lower revenue than Myriad Genetics. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioCryst Pharmaceuticals$450.71M3.94-$88.88M-$0.18-47.06Myriad Genetics$837.60M0.69-$127.30M-$4.28-1.45 Does the media prefer BCRX or MYGN? In the previous week, Myriad Genetics had 2 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 8 mentions for Myriad Genetics and 6 mentions for BioCryst Pharmaceuticals. Myriad Genetics' average media sentiment score of 1.52 beat BioCryst Pharmaceuticals' score of 1.51 indicating that Myriad Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Myriad Genetics 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts rate BCRX or MYGN? BioCryst Pharmaceuticals currently has a consensus target price of $16.70, indicating a potential upside of 97.17%. Myriad Genetics has a consensus target price of $12.45, indicating a potential upside of 100.23%. Given Myriad Genetics' higher possible upside, analysts clearly believe Myriad Genetics is more favorable than BioCryst Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCryst Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90Myriad Genetics 1 Sell rating(s) 9 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.21 Is BCRX or MYGN more profitable? BioCryst Pharmaceuticals has a net margin of -6.41% compared to Myriad Genetics' net margin of -47.45%. BioCryst Pharmaceuticals' return on equity of 0.00% beat Myriad Genetics' return on equity.Company Net Margins Return on Equity Return on Assets BioCryst Pharmaceuticals-6.41% N/A -1.78% Myriad Genetics -47.45%-5.17%-3.44% SummaryBioCryst Pharmaceuticals beats Myriad Genetics on 9 of the 16 factors compared between the two stocks. Get Myriad Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MYGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYGN vs. The Competition Export to ExcelMetricMyriad GeneticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$551.76M$3.10B$5.78B$9.80BDividend YieldN/A2.26%3.95%4.01%P/E Ratio-1.457.3622.5622.49Price / Sales0.69398.26463.84113.07Price / Cash5.9344.6737.7359.36Price / Book1.498.0910.046.68Net Income-$127.30M-$54.08M$3.27B$265.59M7 Day Performance6.69%2.25%3.17%3.42%1 Month Performance42.01%3.41%4.34%1.09%1 Year Performance-77.74%18.61%44.12%23.84% Myriad Genetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYGNMyriad Genetics3.6527 of 5 stars$6.22+4.9%$12.45+100.2%-78.4%$551.76M$837.60M-1.452,700BCRXBioCryst Pharmaceuticals4.1583 of 5 stars$8.39-2.0%$16.70+99.0%+3.5%$1.80B$450.71M-46.61530Positive NewsCLDXCelldex Therapeutics1.7428 of 5 stars$21.93-2.4%$46.67+112.8%-40.8%$1.49B$7.02M-7.29150News CoverageNVAXNovavax4.5341 of 5 stars$7.52-4.1%$15.57+107.1%-32.0%$1.27B$682.16M3.301,990News CoverageAnalyst ForecastGap UpINVAInnoviva4.4843 of 5 stars$19.76-2.0%$42.75+116.3%+3.8%$1.27B$358.71M63.74100MNKDMannKind3.2807 of 5 stars$3.90-5.1%$9.71+149.1%-16.0%$1.26B$285.50M35.46400News CoverageAnalyst ForecastDVAXDynavax Technologies4.6928 of 5 stars$10.39-1.0%$24.33+134.2%-8.5%$1.23B$277.25M-22.59350OPKOPKO Health4.4255 of 5 stars$1.39-1.4%$2.75+97.8%-13.9%$1.12B$713.10M-5.562,997Positive NewsGERNGeron2.9718 of 5 stars$1.42-2.7%$4.19+194.9%-69.7%$931.51M$76.99M-10.92229RIGLRigel Pharmaceuticals1.6331 of 5 stars$40.74-1.8%$38.20-6.2%+200.8%$744.40M$179.28M7.53160ZBIOZenas BioPharma1.5342 of 5 stars$16.56-3.2%$36.67+121.4%N/A$720.09M$5M0.00N/A Related Companies and Tools Related Companies BCRX Alternatives CLDX Alternatives NVAX Alternatives INVA Alternatives MNKD Alternatives DVAX Alternatives OPK Alternatives GERN Alternatives RIGL Alternatives ZBIO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MYGN) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myriad Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Myriad Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access